Forest Laboratories Announces Court Sets New Trial Date for Lexapro Patent Challenge
April 28 2005 - 5:40PM
PR Newswire (US)
Forest Laboratories Announces Court Sets New Trial Date for Lexapro
Patent Challenge NEW YORK, April 28 /PRNewswire-FirstCall/ --
Forest Laboratories, Inc. (NYSE:FRX) reported that today the U.S.
District Court for the District of Delaware has rescheduled opening
arguments from May 9, 2005 to December 5, 2005 for the trial
related to patent litigation regarding the SSRI antidepressant
Lexapro(R). Forest Laboratories, Inc., Forest Laboratories Ireland
Ltd. and H. Lundbeck A/S are plaintiffs with co-defendants being
Ivax Pharmaceuticals, Inc / Cipla Ltd. and Alphapharm Pty Ltd. The
reason for the delay is that defendant Alphapharm Pty Ltd. has
alleged that H. Lundbeck A/S destroyed relevant evidence. In
response the Court will appoint a Special Master to investigate the
matter prior to opening arguments. Forest remains confident in the
strength of the Lexapro patent. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) About
Forest Laboratories and Its Products Forest Laboratories' growing
line of products includes: Lexapro(R) (escitalopram oxalate), an
SSRI antidepressant indicated for the initial and maintenance
treatment of major depressive disorder and for generalized anxiety
disorder in adults; Namenda(R) (memantine HCl), an
N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the
treatment of moderate to severe Alzheimer's disease; Benicar(R)*
(olmesartan medoxomil), an angiotensin receptor blocker indicated
for the treatment of hypertension; Benicar* HCT(R) (olmesartan
medoxomil hydrochlorothiazide), an angiotensin receptor blocker and
diuretic combination product indicated for the second-line
treatment of hypertension; Campral(R)* (acamprosate calcium), a
glutamate receptor modulator, indicated for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation in combination with psychosocial
support; and Combunox(TM) (Oxycodone HCl and Ibuprofen), an opioid
and NSAID combination indicated for the short-term management of
acute, moderate to severe pain. Except for the historical
information contained herein, this release contains
"forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA
approvals, acceptance and demand for new pharmaceutical products,
the impact of competitive products and pricing, the timely
development and launch of new products and the risk factors listed
from time to time in the Company's SEC reports, including the
Company's Annual Report on Form 10-K for the fiscal year ended
March 31, 2004, and on form 10-Q for the periods ended June 30,
September 30, and December 31, 2004. *Benicar is a registered
trademark of Sankyo Pharma, Inc., and Campral is a registered
trademark under license from Merck Sante s.a.s., subsidiary of
Merck KGaA, Darmstadt, Germany.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO DATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President-Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714 Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024